Research Analysts Offer Predictions for MBRX Q4 Earnings

Moleculin Biotech, Inc. (NASDAQ:MBRX) – Equities research analysts at HC Wainwright issued their Q4 2025 earnings per share estimates for Moleculin Biotech in a report issued on Monday, June 9th. HC Wainwright analyst S. Nik anticipates that the company will post earnings of ($0.39) per share for the quarter. HC Wainwright has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Moleculin Biotech’s current full-year earnings is ($7.98) per share.

Several other equities analysts have also recently issued reports on MBRX. Maxim Group upgraded Moleculin Biotech from a “hold” rating to a “buy” rating and set a $4.00 price target on the stock in a research report on Tuesday, March 25th. Wall Street Zen upgraded Moleculin Biotech to a “sell” rating in a research note on Wednesday, March 26th.

Moleculin Biotech Trading Down 1.2%

Shares of NASDAQ MBRX opened at $0.66 on Tuesday. Moleculin Biotech has a twelve month low of $0.40 and a twelve month high of $4.90. The stock has a 50 day moving average of $0.91 and a two-hundred day moving average of $1.37.

Moleculin Biotech (NASDAQ:MBRX) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.02. During the same period in the previous year, the firm posted ($2.02) earnings per share.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Moleculin Biotech stock. Armistice Capital LLC increased its position in Moleculin Biotech, Inc. (NASDAQ:MBRX) by 293.6% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,250,000 shares of the company’s stock after acquiring an additional 932,414 shares during the period. Armistice Capital LLC owned approximately 8.93% of Moleculin Biotech worth $1,217,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.